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Apocrine breast carcinoma as an extremely rare breast 
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 Apocrine carcinoma (AC) is a distinctive and rare type of malignancy, counted for 0.3–4% of all breast cancer cases. It does 
not have a particular clinical or radiological features, although it is characterized by the apocrine morphology, estrogen 
receptor-negative and androgen receptor-positive profile. In the present study, among 1122 patients with breast cancer 
only 5 of them were diagnosed with apocrine carcinoma (0.4%). All patients were above 50 years old (51–63, mean: 57). 
Tumor size varied from 1.4 cm to 3.8 cm with a mean size of 2.4 cm, while mean size of all 1122 studied cases counted for 
1.9 cm. Two tumors were classified as high-grade (G3), 2 as G2, and 1 as G1. Four tumors out of 5 did not affect lymph nodes 
(pN0 stage), whereas 1 was classified as pN2 with 9/19 regional lymph nodes affected. This observation was consistent 
with the whole studied group, in which pN0 stage made up the largest percentage. Presented results suggest that AC is 
less frequent in premenopausal patients. AC tends to present as invasive malignancy without nodal involvement and is 
usually characterized by relatively less aggressive biological behavior compared to other histological types of breast cancer. 
Due to the fact that AC is definitely a rare type of breast cancer, modern medicine has still limited treatment options to 
offer. Further research needs to be conducted in order to develop target therapies for this carcinoma.
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Introduction
According to estimations performed in 2017 by American 
Cancer Society, breast cancer (BC) is expected to reach 30% 
of all new cancers diagnosed among women [1]. Apocri-
ne carcinoma (AC) is one of the rarest histological types of 
this malignancy, comprising from 0.3% to 4% of all cases 
[2]. ACs are usually estrogen receptor-negative (ER–), pro-
gesterone receptor-negative (PR–), but in 100% of cases 
androgen receptor-positive (AR+). This observation leads 
to extensive interest in possible treatment encompassing 
androgen antagonists [3]. On the other hand, about 30% of 
AC cases are HER-positive, which enables another treatment 
possibility with monoclonal antibodies targeting this protein. 
Consequently, 70% of cases without HER2 expression might 
be proposed as a subtype of triple-negative breast cancer 
(TNBC). However, this connection may be misleading due to 
the fact that AC is characterized by AR positive expression 
being unparalleled in TNBC [3, 4].
Aim of the study
The aim of the study was to assess histological grade (G), tumor 
size (pT), regional lymph node status (pN) and expression of ER, 
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PR and HER2 in apocrine carcinoma of the breast in comparison 
to other studied types of breast cancer. 
Material and methods
The material consisted of 1122 tissue blocks derived from 
patients suffering from breast cancer. The analyzed material 
came from biopsies, excisional biopsies and modified radical 
mastectomies. Histological and immunohistochemical studies 
were performed. Apocrine carcinoma was detected in 5 out of 
1122 samples. Analyzed samples were fixed in 10% buffered 
formalin phosphate. After 24-hours fixation, materials were 
dehydrated and then paraffin blocks were cut into sections 
4 μm thick. Preparations stained with hematoxylin and eosin 
were used for defining type of neoplasm according to WHO 
classification and grading. Immunohistochemical staining was 
performed for assessing expression of ER, PR and HER2. Eval-
uation of these markers was performed as follows: ER and PR 
were categorized as negative – (0%), low positive – (1–10%); 
nuclear staining in >10% of tumor cells was considered positive 
both for ER and PR. HER2 expression was determined using 
HerceptTestTM (Code: K5204, DAKO, Santa Clara, United States).
Results
Five cases of apocrine carcinoma represented 0.4% of all 
1122 studied breast cancer samples. All 5 patients were abo-
ve 50 years old (51–63; mean: 57). Four tumors out of 5 were 
detected in the left breast. 2 samples were classified as high 
grade (G3), 2 as G2, and 1 as G1. Tumor size varied from 1.4 cm 
to 3.8 cm as follows: 1.4 cm (pT1c), 1.7 cm (pT1c), 2 samples 
– 2.5 cm (pT2), 3.8 cm (pT2). Mean size was 2.4 cm, whereas 
mean size of all 1122 studied samples reached 1.9 cm. Four 
out of 5 studied cancers presented without nodal involvement 
(pN0), while only 1 was classified as pN2 with metastases in 
9/19 lymph nodes. This investigation was in consistency with 
the whole analyzed group, in which pN0 comprised the largest 
percentage. Distant metastases (M) were not observed in any 
of the investigated AC cases. As far as immunohistochemistry 
is concerned, none of 5 analyzed cases expressed ER or PR. 
Positive expression of HER2 was detected in only 1 sample, 
which accounted for 20% of studied AC cases. Detailed data 
on the examined AC cases are presented in the table (Table I). 
Discussion
Breast cancer is the most common malignancy among women 
worldwide [5]. ER, PR and HER2 are commonly used for dia-
gnosing process and choosing appropriate treatment options 
for particular types of breast cancer. However, AR detected 
in 100% of ACs is an emerging potential target for accurate 
diagnosis and targeted treatment [6]. 
AC is specific for the group of postmenopausal women 
[3, 7–9]. This was confirmed in the present study, as the mean 
age of all diagnosed women was 57 years. Given tumor size, all 
cases were presented in low stage – none of them reached pT3 
stage. Similar results were obtained by Mills et al. (2016) [3] – 
the majority of tumors were assessed as pT1 or pT2 making up 
90% of studied cases – and by Seo et al. (2015) [7] – all lesions 
were described in the range between 1.2 cm and 2.2 cm. As 
far as nodal involvement is concerned, the vast majority of 
analyzed tumors were assessed pN0, as in 4 out of 5 cases 
regional lymph nodes involvement has not been observed. 
Interestingly, the opposite results were achieved by Liu et al. 
(2015) [6] – they described molecular apocrine breast cancer 
(defined as each BC presenting ER–/PR–/AR+ profile) with 
tendency to affect more lymph nodes than other studied 
types of BC. However, so defined apocrine cancer did not 
exhibit all the histopathological traits that were characteristic 
of classical ACs. Moreover, they detected a close association 
between lymph node invasion and expression of gross cys-
tic disease fluid protein 15 (GCDFP15) in AC patients. This 
molecule is regulated by AR and was proposed as a negative 
marker for AC patients outcome due to significant correlation 
with shorter disease-free survival (DFS) and overall survival 
(OS). Unfortunately, as mentioned above, those results cannot 
have a strict reference into a histologically defined apocrine 
carcinoma, because both groups of AC, defined molecularly 
and histologically, are not completely synonymous.
Table I. Detailed histopathological characteristics of analyzed apocrine breast cancer cases


































Left 2.5 – 2 2 9/19 0 IIIA 2 – – 2+
63 Postoperative 
material
Left 1.4 – 1c 0 0/18 0 IB 1 – – 0
56 Postoperative 
material
Left 1.7 – 1c 0 0/20 0 IB 2 – – 0
57 Postoperative 
material
Left 3.8 + 2 0 0/3 0 IIA 3 – – 0
51 Postoperative 
material
Right 2.5 – 2 0 0/16 0 IIA 3 – – 0
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Some studies describe AC without HER2 expression as tri-
ple-negative apocrine carcinoma (TNAC) [9]. In the present stu-
dy 4 out of 5 ACs presented HER2 negativity. In the study con-
ducted by Meattini et al. (2018) [9], TNAC were characterized by 
lower Ki-67 index and better survival in comparison to group 
of non-apocrine triple negative tumors. Their multivariate ana-
lysis demonstrated that the only significant factor for OS was 
the histology of TNAC. On the other hand, Vranic et al. (2010) 
[10] highlighted the necessity of considering apocrine breast 
cancers as molecularly diverse group and distinguishing pure 
apocrine carcinomas and apocrine-like carcinomas. According 
to their study, pure apocrine carcinomas predominantly be-
long to either HER2 overexpressing or TNBC groups, whereas 
apocrine-like carcinomas to luminal phenotype (both A and 
B). What is more, study results suggested that EGFR expression 
may by essential for the proper identification of apocrine 
carcinomas when considering doubtful HER2-positive APc.
Numerous studies have proved the prognostic potential 
of AR expression in BC and its association with more favorable 
prognosis. Moreover, several experiments discovered a cros-
stalk between AR and ER by inhibiting each other’s activity 
[11]. Due to emerging role of AR in BCs, new therapies are 
consequently implemented. One of them encompasses bi-
calutamide – a nonsteroidal antiandrogen originally used in 
the treatment of prostate cancer [12]. The study conducted by 
Huang et al. (2017) [13] revealed the mechanism responsible 
for effective treatment with bicalutamide usage. This nonste-
roidal antiandrogen was proved to block androgen-stimulated 
oncogenic AR and Wnt/β-catenin signaling and as an effect to 
inhibit the growth of AR+/ER– breast cancer. 
Conclusions
AC is a distinctive and rare type of breast cancer. It has a tenden-
cy to affect older population of females. Although tumors are 
usually diagnosed in larger average size, they tend to present 
without regional lymph nodes involvement. Slightly different 
results concerning characteristics of BC subgroup might be 
explained by small groups incorporated into different analysis. 
Owing to AR positive expression, new therapies are develo-
ped for more specific treatment, however further research is 
still needed to develop target therapies for this malignancy. 
Associations described in the present study should be investi-
gated further, as the group of patients was small, even though 
representing a rare histological subtype of breast cancer. 
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